Neuberger Berman Group LLC Increases Stock Position in Biohaven Ltd. (NYSE:BHVN)

Neuberger Berman Group LLC boosted its position in Biohaven Ltd. (NYSE:BHVN - Free Report) by 2,953.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 129,465 shares of the company's stock after buying an additional 125,225 shares during the quarter. Neuberger Berman Group LLC owned approximately 0.13% of Biohaven worth $4,836,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. Spire Wealth Management bought a new stake in shares of Biohaven in the 4th quarter valued at about $56,000. Amalgamated Bank increased its stake in Biohaven by 21.9% in the 4th quarter. Amalgamated Bank now owns 2,929 shares of the company's stock worth $109,000 after purchasing an additional 527 shares during the period. US Bancorp DE lifted its position in Biohaven by 36.7% in the fourth quarter. US Bancorp DE now owns 2,971 shares of the company's stock valued at $111,000 after purchasing an additional 798 shares during the last quarter. KBC Group NV boosted its stake in shares of Biohaven by 50.1% during the fourth quarter. KBC Group NV now owns 3,377 shares of the company's stock valued at $126,000 after purchasing an additional 1,127 shares during the period. Finally, Diversified Trust Co grew its holdings in shares of Biohaven by 16.6% in the fourth quarter. Diversified Trust Co now owns 5,585 shares of the company's stock worth $209,000 after purchasing an additional 795 shares during the last quarter. 88.78% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the stock. HC Wainwright reiterated a "buy" rating and set a $54.00 price target on shares of Biohaven in a report on Tuesday, March 4th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Biohaven in a research note on Tuesday, December 17th. Morgan Stanley cut their target price on Biohaven from $69.00 to $63.00 and set an "overweight" rating on the stock in a research note on Friday, March 7th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $61.00 price target on shares of Biohaven in a research report on Tuesday, March 4th. Finally, JPMorgan Chase & Co. cut their price objective on Biohaven from $72.00 to $68.00 and set an "overweight" rating on the stock in a research report on Wednesday, March 5th. Fourteen investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Biohaven has an average rating of "Buy" and an average price target of $62.77.

Remove Ads

Biohaven Trading Up 0.3 %

Biohaven stock traded up $0.05 on Tuesday, hitting $18.56. 1,127,581 shares of the stock traded hands, compared to its average volume of 1,118,164. Biohaven Ltd. has a 1 year low of $15.79 and a 1 year high of $55.70. The firm has a market cap of $1.89 billion, a P/E ratio of -1.99 and a beta of 1.33. The business's fifty day simple moving average is $29.63 and its 200 day simple moving average is $39.12.

Biohaven (NYSE:BHVN - Get Free Report) last issued its quarterly earnings results on Monday, March 3rd. The company reported ($1.85) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.56) by ($0.29). As a group, analysts predict that Biohaven Ltd. will post -8.9 earnings per share for the current year.

Insider Transactions at Biohaven

In related news, Director John W. Childs purchased 32,700 shares of Biohaven stock in a transaction dated Tuesday, March 4th. The stock was purchased at an average cost of $30.47 per share, for a total transaction of $996,369.00. Following the completion of the acquisition, the director now directly owns 2,320,571 shares of the company's stock, valued at $70,707,798.37. The trade was a 1.43 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 16.00% of the company's stock.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.